Table 2

Summary of trials of transjugular intrahepatic portosystemic stent-shunt for refractory ascites and hepatic hydrothorax

Study	Indication	n	Response (complete) (%)	1 year survival (%)	Prognostic factors for response
Crenshaw and colleagues26	Refractory ascites	54	79 (57)	52	NS
Williams and colleagues27	Refractory ascites	15	53 (40)	54	Renal insufficiency
Rees and colleagues28	Refractory ascites	25	33	67	NS
Nazarian and colleagues29	Refractory ascites	50	62	NS	Creatinine, bilirubin
Forrest and colleagues30	Refractory ascites	18	27	50	Creatinine, bilirubin
Lebrec and colleagues25	Refractory ascites	13/12	23	29 (2 years)	Child's class
Ochs and colleagues32	Refractory ascites	50	92 (74)	55	Nil
Gordon and colleagues33	Hepatic hydrothorax	24	79 (58)	57	Nil
Jeffries and colleagues34	Hepatic hydrothorax	12	58	58	NS